UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for breast cancer in the United Kingdom. Explore treatment pathways for HER2-positive, HR+/HER2-negative, and triple-negative breast cancer.
Breast cancer is the most common cancer in the UK, with around 55,000 new cases each year. Treatment has advanced enormously - modern therapies including targeted treatments, immunotherapy, and personalised medicine have dramatically improved outcomes. Clinical trials offer access to the newest treatments before they're widely available.
The main subtypes are: HR+/HER2- (hormone receptor positive, HER2 negative - the most common, ~70%), HER2-positive (~15-20%, responds to targeted therapies like trastuzumab), and Triple Negative (~15%, more common in younger women, treated with chemotherapy and immunotherapy). Each type has different treatment pathways and clinical trial opportunities.
First-line treatment depends on subtype: HR+ cancers use hormone therapy (letrozole, tamoxifen) with CDK4/6 inhibitors (palbociclib, ribociclib). HER2+ uses trastuzumab + pertuzumab + chemotherapy. TNBC uses immunotherapy (pembrolizumab) + chemotherapy. Second-line options include antibody-drug conjugates like trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan.
Clinical trials for breast cancer in the UK are available through the NHS, with major trial centres at The Royal Marsden, Christie Hospital, and university hospitals nationwide. Trials range from early-phase studies of new targeted drugs to large phase 3 studies comparing standard treatments. Our pathway explorer shows you exactly when trials become available in your treatment journey.
96 recruiting trials — 4 early-stage, 1 locally advanced, 43 recurrent or metastatic, 48 stage not specified
Free AI-powered matching - no signup required
Search mammary carcinoma Trials →